Compass Pathways (NASDAQ:CMPS) Shares Gap Down – Should You Sell?

Posted by Brian Himes on Jul 7th, 2026

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS – Get Free Report)’s stock price gapped down prior to trading on Tuesday . The stock had previously closed at $12.84, but opened at $11.75. Compass Pathways shares last traded at $11.8670, with a volume of 3,940,334 shares traded.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. UBS Group set a $18.00 price target on Compass Pathways in a report on Thursday, May 7th. Canaccord Genuity Group lifted their price objective on Compass Pathways from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Friday, June 26th. Raymond James Financial reaffirmed a “buy” rating on shares of Compass Pathways in a research report on Friday, May 22nd. TD Cowen reiterated a “buy” rating on shares of Compass Pathways in a research note on Monday, June 1st. Finally, Wall Street Zen raised shares of Compass Pathways from a “strong sell” rating to a “hold” rating in a research report on Saturday, May 16th. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $23.10.

View Our Latest Stock Report on CMPS

Compass Pathways Stock Down 3.8%

The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.32 and a current ratio of 3.32. The firm has a market capitalization of $1.67 billion, a P/E ratio of -3.91 and a beta of 2.47. The stock has a fifty day moving average price of $11.63 and a two-hundred day moving average price of $8.43.

Compass Pathways (NASDAQ:CMPS – Get Free Report) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.15. Research analysts forecast that Compass Pathways PLC Sponsored ADR will post -1.24 EPS for the current year.

Hedge Funds Weigh In On Compass Pathways

Institutional investors have recently made changes to their positions in the stock. EverSource Wealth Advisors LLC grew its stake in Compass Pathways by 67.7% during the 1st quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock worth $26,000 after buying an additional 1,920 shares during the last quarter. Persistent Asset Partners Ltd acquired a new stake in shares of Compass Pathways in the 4th quarter worth approximately $38,000. Parallel Advisors LLC boosted its stake in Compass Pathways by 8,450.6% during the 1st quarter. Parallel Advisors LLC now owns 7,268 shares of the company’s stock valued at $40,000 after purchasing an additional 7,183 shares in the last quarter. Advisory Services Network LLC bought a new position in Compass Pathways during the third quarter valued at about $41,000. Finally, North Star Investment Management Corp. grew its stake in shares of Compass Pathways by 1,354.0% in the 1st quarter. North Star Investment Management Corp. now owns 7,517 shares of the company’s stock worth $42,000 after purchasing an additional 7,000 shares during the last quarter. 46.19% of the stock is owned by institutional investors.

Compass Pathways Company Profile

(Get Free Report)

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.